Skip to main content Skip to search Skip to main navigation

Swissmedic: Adoption of EU Regulation 2025/1234 on use of Electronical Instructions for Medical Devices

On 26 June 2025, Implementing Regulation (EU) 2025/1234 was published in the Official Journal of the EU, entering into force on 16 July 2025. It amends Implementing Regulation (EU) 2021/2226, which sets out the requirements for the electronic provision of instructions for use for medical devices. The regulations have been expanded. Switzerland is adopting these requirements immediately, initially without any additional amendments to the Swiss MepV (Medical Devices Ordinance).

In brief:

  • Products intended for professional users now have an extended scope of application for electronic instructions for use, covering all medical devices and their accessories.
  • Products without a medical purpose, according to Annex XVI of the EU MDR, and 'legacy devices' are also subject to an extended scope of application if they are intended for use by professional users.
  • Products used by lay persons still require instructions in paper form.

Regulation (EU) No 207/2012 of 9 March 2012, listed in Annex I of the EU MDR, is hereby repealed.


Source:

Swissmedic: News & Updates

EU: Implementing Regulation (EU) 2025/1234


Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

Outsourced Activities in the GDP Environment Part II: Contractual Agreements

Outsourced Activities in the GDP Environment Part II: Contractual Agreements

When outsourcing GDP activities, there is a need for concrete delimitation of responsibilities between a client and a contractor. Read more about the goals and the contents of a quality agreement in the following excerpt from GMP:KnowHow Pharmalogistics (GDP).

Read more
Question of the Week | GMP-Verlag

What are the Benefits and Limitations of Passive Temperature-Controlled Containers for Drug Transport?

Here's the answer:
Read more
FDA: Adjustment of Nitrosamine Limits for Short-Term Use Medicines

FDA: Adjustment of Nitrosamine Limits for Short-Term Use Medicines

The FDA has updated its recommendations on Acceptable Intake (AI) limits for nitrosamine impurities. Under certain conditions, the Agency now accepts a Less-Than-Lifetime (LTL) adjustment of AI limits for medicinal products that are not intended for lifetime use. This also represents an alignment with the LTL concept of ICH M7(R2).
Read more
Swissmedic: SMS Registration Becomes Prerequisite for GMP Certificates

Swissmedic: SMS Registration Becomes Prerequisite for GMP Certificates

As of 15 November 2026, active substances must be registered in the EMA's Substance Management Services (SMS) database before Swissmedic can include them in establishment licences and GMP certificates for active substance manufacturers. The new requirement results from modifications to the EudraGMDP database.
Read more
News: EMA

EMA: New Q&As for Biological Medicinal Products

The EMA has added a new section to its Q&As on biological medicinal products addressing medicinal products containing secretomes or extracellular vesicles (EVs) obtained from human or animal cells.
Read more
News: Europe

EU: Council Adopts the Pharmaceutical Package

On 28 September 2026, the Council of the European Union adopted the EU pharmaceutical package, marking another important step in the legislative process for the comprehensive reform of EU pharmaceutical legislation.
Read more
Previous
Next